Compare ASTE & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTE | NBTX |
|---|---|---|
| Founded | 1972 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 2002 | 2018 |
| Metric | ASTE | NBTX |
|---|---|---|
| Price | $63.12 | $36.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $26.00 |
| AVG Volume (30 Days) | ★ 199.0K | 28.1K |
| Earning Date | 05-27-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.84% | N/A |
| EPS Growth | ★ 784.21 | N/A |
| EPS | ★ 1.68 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.00 | N/A |
| Revenue Next Year | $4.13 | $11.73 |
| P/E Ratio | $36.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.65 | $2.95 |
| 52 Week High | $64.37 | $33.80 |
| Indicator | ASTE | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 68.67 | 76.81 |
| Support Level | $44.05 | $20.11 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 2.83 | 1.77 |
| MACD | 0.16 | 0.89 |
| Stochastic Oscillator | 84.69 | 89.41 |
Astec Industries Inc designs and manufactures equipment and components used in road construction and other development activities. Its products are used through the entire process of building roads, from mining and crushing materials to creating the road surface. The company manufactures a line of plants, pavers, vehicles, and machines to mix and transform materials into construction components. It has two operating segments: infrastructure solutions generating maximum revenue and materials solutions. The majority of sales are derived from the United States. Its customers are asphalt producers, highway and heavy equipment contractors, ready mix concrete producers, demolition recycling markets, sand and gravel producers, open mine operators, quarry operators, and others.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.